Elinor Hortle1,2, Khelsey E Johnson3, Matt D Johansen1, Tuong Nguyen1, Jordan A Shavit4, Warwick J Britton1,2, David M Tobin3, Stefan H Oehlers1,2. 1. Tuberculosis Research Program Centenary Institute, The University of Sydney, Camperdown, Australia. 2. The University of Sydney, Central Clinical School and Marie Bashir Institute, Camperdown, Australia. 3. Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina. 4. Department of Pediatrics and Cellular and Molecular Biology Program, University of Michigan, Ann Arbor.
Abstract
BACKGROUND: Infection-induced thrombocytosis is a clinically important complication of tuberculosis infection. Recent studies have highlighted the utility of aspirin as a host-directed therapy modulating the inflammatory response to infection but have not investigated the possibility that the effect of aspirin is related to an antiplatelet mode of action. METHODS: In this study, we utilize the zebrafish-Mycobacterium marinum model to show mycobacteria drive host hemostasis through the formation of granulomas. Treatment of infected zebrafish with aspirin markedly reduced mycobacterial burden. This effect is reproduced by treatment with platelet-specific glycoprotein IIb/IIIa inhibitors demonstrating a detrimental role for infection-induced thrombocyte activation. RESULTS: We find that the reduction in mycobacterial burden is dependent on macrophages and granuloma formation, providing the first in vivo experimental evidence that infection-induced platelet activation compromises protective host immunity to mycobacterial infection. CONCLUSIONS: Our study illuminates platelet activation as an efficacious target of aspirin, a widely available and affordable host-directed therapy candidate for tuberculosis.
BACKGROUND: Infection-induced thrombocytosis is a clinically important complication of tuberculosis infection. Recent studies have highlighted the utility of aspirin as a host-directed therapy modulating the inflammatory response to infection but have not investigated the possibility that the effect of aspirin is related to an antiplatelet mode of action. METHODS: In this study, we utilize the zebrafish-Mycobacterium marinum model to show mycobacteria drive host hemostasis through the formation of granulomas. Treatment of infected zebrafish with aspirin markedly reduced mycobacterial burden. This effect is reproduced by treatment with platelet-specific glycoprotein IIb/IIIa inhibitors demonstrating a detrimental role for infection-induced thrombocyte activation. RESULTS: We find that the reduction in mycobacterial burden is dependent on macrophages and granuloma formation, providing the first in vivo experimental evidence that infection-induced platelet activation compromises protective host immunity to mycobacterial infection. CONCLUSIONS: Our study illuminates platelet activation as an efficacious target of aspirin, a widely available and affordable host-directed therapy candidate for tuberculosis.
Authors: Jean-Yves Tinevez; Nick Perry; Johannes Schindelin; Genevieve M Hoopes; Gregory D Reynolds; Emmanuel Laplantine; Sebastian Y Bednarek; Spencer L Shorte; Kevin W Eliceiri Journal: Methods Date: 2016-10-03 Impact factor: 3.608
Authors: Florian Gaertner; Zerkah Ahmad; Gerhild Rosenberger; Shuxia Fan; Leo Nicolai; Benjamin Busch; Gökce Yavuz; Manja Luckner; Hellen Ishikawa-Ankerhold; Roman Hennel; Alexandre Benechet; Michael Lorenz; Sue Chandraratne; Irene Schubert; Sebastian Helmer; Bianca Striednig; Konstantin Stark; Marek Janko; Ralph T Böttcher; Admar Verschoor; Catherine Leon; Christian Gachet; Thomas Gudermann; Michael Mederos Y Schnitzler; Zachary Pincus; Matteo Iannacone; Rainer Haas; Gerhard Wanner; Kirsten Lauber; Michael Sixt; Steffen Massberg Journal: Cell Date: 2017-11-30 Impact factor: 41.582
Authors: K Peerlinck; I De Lepeleire; M Goldberg; D Farrell; J Barrett; E Hand; D Panebianco; H Deckmyn; J Vermylen; J Arnout Journal: Circulation Date: 1993-10 Impact factor: 29.690
Authors: Mark R Cronan; Rebecca W Beerman; Allison F Rosenberg; Joseph W Saelens; Matthew G Johnson; Stefan H Oehlers; Dana M Sisk; Kristen L Jurcic Smith; Neil A Medvitz; Sara E Miller; Le A Trinh; Scott E Fraser; John F Madden; Joanne Turner; Jason E Stout; Sunhee Lee; David M Tobin Journal: Immunity Date: 2016-10-18 Impact factor: 31.745
Authors: Vera Marie Kroesen; Paula Rodríguez-Martínez; Eric García; Yaiza Rosales; Jorge Díaz; Montse Martín-Céspedes; Gustavo Tapia; Maria Rosa Sarrias; Pere-Joan Cardona; Cristina Vilaplana Journal: Front Immunol Date: 2018-04-23 Impact factor: 7.561
Authors: Julia Y Kam; Tina Cheng; Danielle C Garland; Warwick J Britton; David M Tobin; Stefan H Oehlers Journal: Pathog Dis Date: 2022-04-29 Impact factor: 3.951
Authors: Elinor Hortle; Vi Lt Tran; Kathryn Wright; Angela Rm Fontaine; Natalia Pinello; Matthew B O'Rourke; Justin J-L Wong; Philip M Hansbro; Warwick J Britton; Stefan H Oehlers Journal: Life Sci Alliance Date: 2022-05-11
Authors: Pradeep Manuneedhi Cholan; Alvin Han; Brad R Woodie; Maxinne Watchon; Angela Rm Kurz; Angela S Laird; Warwick J Britton; Lihua Ye; Zachary C Holmes; Jessica R McCann; Lawrence A David; John F Rawls; Stefan H Oehlers Journal: Gut Microbes Date: 2020-11-09